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A newly described glomerulotubular feedback loop may
explain the relationship between glomerular damage,
epitope spreading, tubulointerstitial nephritis, proteinuria as
a progression factor, and the importance of the local milieu
in kidney damage. It also opens the horizons for exciting
innovative approaches to therapy of both acute and chronic
kidney diseases.
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B AND T CELLS IN GLOMERULONEPHRITIS
In the beginning there were B cells. There were, of course,
other cells observed in experimental and human glomer-
ulonephritis (GN), but the dictum in the early studies of
experimental autoimmune GN (EAG) demanded that the
only important lymphocyte was the B cell, because of
secreted immunoglobins, which fixed to antigens in the
kidney and induced GN. So strong was this theory that
suggestions to the contrary were soundly derided.1,2 How-
ever, increasing evidence suggested that this paradigm was
only partly true. Two models were used to study GN. In the
first model of nephrotoxic serum nephritis, heterologous
antibodies were administered, fixed to the glomerular
basement membrane (GBM), and induced an inflammatory
response. Although this was a planted-antigen model and not
truly an autoimmune GN, and was not directly pertinent to
the human condition, nonetheless, it provided an excellent
vehicle to examine glomerular inflammation. Interestingly,
this disease model with antibodies only on the GBM was also
associated with tubulointerstitial nephritis (TIN). The other
model, described by Steblay, involved induction of an
autoimmune response to self-antigens in the GBM. This
was most analogous to Goodpasture’s syndrome in man.
Severe disease could be transferred to monkeys by eluates
from a Goodpasture patient’s kidney, but only transient mild
disease was transferred by circulating antibodies.3 The ability
of the cellular immune system alone to induce EAG was first
documented by studies that we performed in an avian model.
Chickens were rendered antibody deficient by bursectomy
and demonstrated a normal intact delayed hypersensitivity
(DTH) system.4 Upon immunization with GBM, florid GN
developed with no antibody response and no antibody
deposits on the GBM. The disease could be transferred by
cells but not antibodies.
Few tools were present in those days to examine the types
of cells involved, the pathogenic mechanisms or the true
interrelationship between cells and antibodies. Over the
ensuing decades, the availability of monoclonal antibodies,
recombinant proteins, knock-out and knock-in mice, trans-
genic animals, and a host of other sophisticated tools have
resulted in an increasingly complicated, yet clearer picture of
pathogenic processes. It is clear that B and T cells, indeed
many cells, are involved in the pathogenesis of autoimmune
GN, and in many other glomerular diseases (Figure 1).5–7
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Biopsies from humans with GN contain macrophages,
CD4þ , and CD8þ cells within the interstitial compartment
but also in the glomeruli, with dendritic cells (DCs) isolated
to the interstitium.8–10 Indeed, antibody-negative GN, first
described by Stilmant et al.11 (pauci-immune disease), is
phenotypically indistinguishable from many other types of
GN with antibody deposits and was postulated to be a cell-
mediated process. Identification of the responsible antigen of
Goodpasture’s syndrome, the non-collagenous domain of a3
type IV collagen (Col4A3) with resultant production of
recombinant proteins of Col4A3, provided yet further
opportunities to investigate the role of T cells in the
pathogenesis of GN. Work from many laboratories demon-
strated that immunization with Col4A3 could result in GN
without antibodies, that multiple interventions with mono-
clonal antibodies or immunosuppressive drugs that targeted
T cells could suppress the disease, and that tolerance could be
induced, all suggesting a significant role of T cells.7,12–14 The
disease could be transferred with antibodies, but could also
be transferred with CD4þ T cells derived from nephritic
animals.15,16 The latter disease took a long time to develop,
and was marked by an intense TIN followed at a later time by
GN. No antibodies were detected in these rats and none
of the transferred cells elaborated anti-GBM antibody.
Identification of the nephritogenic peptides in this model
allowed the demonstration that a pure T-cell epitope was
capable of inducing GN without antibody. This also allowed
the demonstration that both intra- and intermolecular
epitope spreading occurred consequent to T-cell-induced
injury.12,17,18 The nephritogenic epitope was restricted to
MHC Class II and epitope spreading occurred through local
antigen presentation within the kidney draining lymph nodes
(KDLNs).19,20 These studies were thus consistent with
initiation of a T-cell response to antigen, resulting in GBM
damage, release of additional epitopes from the GBM with
consequent autoimmunization, epitope spreading, and am-
plification of the disease process. The exact mechanism of
how that might occur was not clear, nor was attention paid to
the intense TIN seen in these animals as seen in human
disease, consisting of macrophages, CD4þ , and CD8þ cells.21
GLOMERULOSCLEROSIS AND TIN WITH GN
Glomerulosclerosis and TIN are observed in many human
and animal models of immune and nonimmune glomerular
damages. Indeed, the severity of chronic TIN is the best
correlate of decline in kidney function and long-term
outcome rather than the severity of glomerular histological
damage.22 This correlates with proteinuria, and the animal
models induced with protein-overload proteinuria, as well as
human clinical studies, document a pivotal role of protei-
nuria in disease progression.23 In fact, proteinuria reduction
is now a mainstay of slowing progression of chronic kidney
disease (CKD). For decades renal pathologists assured us that
glomerulosclerosis and TIN in kidney diseases are the normal
consequence of any type of damage and is simply a
‘mopping-up’, scarring-down process as the kidney attempts
to remodel. The mechanism for developing TIN is not clear,
but many postulates have been provided to suggest pivotal
roles for upregulation of cytokines/chemokines in response
to filtered proteins that gain access to the interstitial space.
Several recent papers now bring into sharp focus an
exciting model of pathogenesis, which ties together the
concept of glomerular damage with epitope spreading, TIN,
proteinuria-induced disease amplification, and communica-
tion with the glomerulus through tubular mechanisms—
a new form of glomerulotubular feedback. The common
denominators for this model are CD8þ T-lymphocytes
and DCs.
CD8þ CELLS
CD8þ T cells are important in various types of GN.24 They
are found infiltrating the glomerulus, in the interstitium, and
as periglomerular or tubule-associated infiltrates. In animal
models, anti-CD8 monoclonal antibodies administration can
prevent diseases, including EAG, and other glomerulopathies.
Despite the demonstrated importance of CD8þ T cells in
GN, little information is available regarding their target
molecules and cell types, their activation by accessory cells,
and their interaction with other kidney cells during
pathogenesis. In two recent studies, the role of CD8þ T-
cells in renal disease has been addressed by the use of a model
antigen delivered to kidney tubules either as naturally
occurring components or as shed transgene products.25,26
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Figure 1 |Cells in GN. Figure 1 represents an aggregate of data
derived from animal models. B cells were classically considered to
be involved in the pathogenesis of GN by elaboration of
immunoglobulin (Ig). Th-17, CD4þ , and CD8þ cells have a
significant role as shown by abrogation of activity leading to
amelioration of GN. Macrophages and peripheral blood leukocyte
(PBL) are essential in the histological changes of GN. All result in a
variable increase in the mesangial matrix, and involvement of the
visceral and parietal epithelial cells. T regulatory cells downregulate
disease. Experimental autoimmune glomerulonephritis
presumably arises secondary to various etiologies, including
broken tolerance, a decrease in suppressor/regulatory cells,
epitope mimetics, exposure of cryptic antigens, and possibly
autoimmunity to complementary peptides.
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The study of Macconi et al.25 considers the contribution of
autoantigens, in this case albumin, to the activation of CD8þ
T cells during kidney injury induced by five-sixths nephrect-
omy, renal mass reduction (RMR). CD8þ T cells are classically
considered to respond only to peptides derived from
intracellular antigens processed by cytosolic proteosomes
and loaded onto MHC-I by a MHC-I assembly and loading
pathway in the endoplasmic reticulum. The significance of
DC cross-presentation in which peptides from extracellular
antigens such as viral particles, apoptotic cells, and soluble
secreted proteins are endocytosed, processed, and loaded
onto MHC-I molecules for presentation to CD8þ T cells has
been increasingly appreciated and the process mechanism is
better understood.27 In their recent study, Macconi et al.
proposed that kidney injury results in the activation of
interstitial renal DCs, which have received albumin protein
fragments captured, degraded, and transported from the
tubular lumen by tubular epithelial cells (TECs). These
activated and albumin-loaded DCs migrate to KDLNs and
prime CD8þ T cells to become effectors specific for the
albumin peptide, which can be seen as MHC class I (MHC-
I)-peptide complexes on renal cell surfaces. The renal cells
then become potential cytotoxicity targets and contribute to
further kidney injury because of CD8þ T-cell killing. By 4
weeks after RMR, significantly more albumin peptide (a.a.
1–24)-specific CD8þ T cells were found in KDLNs. Albu-
min-specific CD8þ T-cell induction was blocked by in-
hibitors of proteosomes, which also reduced TIN and
glomerular damage in vivo in RMR rats. The results suggest
that proteins in the urinary space, transported by TECs, can
activate CD8þ T cells during kidney inflammation and the
DC has a key role in presenting these exogenous proteins by a
proteosome-dependent cross-presentation mechanism. It will
be important in future experiments to identify the renal DC
subsets responsible for the cross-presentation of exogenous
antigen to CD8þ DC and further confirm the role of
proteosomes in this proposed scheme.
In the second study, Heymann et al.26 used a transgenic
mouse host that expresses ovalbumin (OVA) on glomerular
podocytes. Transfer of naı¨ve ovalbumin-specific transgenic
CD8þ (OT-I) or CD4þ (OT-II) T cells alone or together
caused no disease. However, co-injection of naı¨ve OT-I cells
with activated OT-II cells induced inflammation of the
parietal epithelial cells and periglomerular infiltration of
lymphocytes, DCs, and macrophages. Repeated injections of
cells caused progression of TIN, glomerular sclerosis,
proteinuria, and impaired renal function. Finally, the authors
showed that recruited DC, derived from proinflammatory
circulating monocytes rather than resident kidney DC,
infiltrated the kidney, and that DCs were required for the
periglomerular infiltration. This showed not only that CD8þ
effector cells are critical in inducing chronic GN, but also that
glomerular antigens released from podocytes are captured by
DCs and presented to CD8þ T cells for activation, that
transferred antigen-specific CD4þ T cells are required for
CD8þ T-cell-mediated disease induction, and that DC, but
not other kidney MHCIIþ cells are responsible for CD8þ
T-cell activation.
DC IN PATHOGENESIS
The results of these studies touch upon four critical issues
that require further studies. The first is the relative
contributions of TEC’s transcellular transport versus direct
DC uptake of antigens from the tubular lumen for antigen
presentation to T cells. The second issue is whether specific
subsets of DC are responsible for cross-presentation and,
if so, what the subsets are. The third issue concerns the
pathway of extracellular antigen processing and cross-
presentation in DC. The last concerns the role of CD4þ
T cells in CD8þ T-cell activation and GN pathogenesis. To
address these questions, we will briefly review DC in the
kidney, lymphoid organs, and other tissues, with emphasis on
antigen transport and cross-presentation in the mouse
(Figure 2).
DC possesses the distinguishing features that make them
versatile and proficient antigen-presenting cells. These
features are the expression of MHC class II, costimulation
molecules, cytokines for T-cell stimulation, the ability to
mobilize and migrate to visceral and lymphoid organs in
response to antigenic and pathogenic stimuli, maturation
from an antigen-internalizing cell type to an antigen-
presenting cell type, and differentiation into subsets with
differential functional specialization.28 In mouse lymphoid
organs, DCs are classified into three functionally and
phenotypically distinct subsets, the conventional CD8þ and
CD11bþ DC subsets, and the plasmacytoid DC (PDC)
subset. Two additional subsets, the Langerhans cells and the
CD103þ DCs, are associated with epithelial tissues. These
DC subsets are specialized to perform varied antigen-
presentation functions, such as presentation of soluble
antigens to CD4þ T cells, cross-presentation of exogenous
antigens to CD8þ T cells, antiviral functions including viral
antigen presentation and interferon production, and the
secretion of effector molecules comprising chemokines,
cytokines, active oxygen species, NO, and arachidonate
metabolites. Lymphoid CD11bþ DCs, which also express
the 33D1 antigen DCIR2, mediate the CD4þ T-cell
activation by soluble antigens through MHC II.29 Lung
CD11bþ /high DCs also produce high levels of cytokines and
chemokines and differentially express mRNA of enzymes
responsible for active oxygen species, NO, prostaglandins,
and leukotrienes production (Sung SJ, GEO accession
#GSE17322). Splenic CD8þ DCs that express DEC205 are
responsible for the uptake of apoptotic cells, cross-presenta-
tion to CD8þ T cells, and stimulation of Foxp3þ regulatory
T cells.28,30 CD103þ DCs occur as a major population
primarily in epithelial tissues.31,32 They are functionally and
phenotypically similar to CD8þ DCs.32–34 In the intestines,
CD103þ DCs mediate regulatory T-cell induction in a TGF-b-
and retinoic acid-dependent manner.32 In lungs, in which no
CD8þ DCs are present, CD103þ DC mediate cross-
presentation.35 Similar to some gut DCs, CD103þ DC
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express tight junction proteins that enable them to traverse
the lung epithelium to capture airway antigens.31,32 Plasma-
cytoid DCs in mice have a significant role in viral disease by
secreting IFN-a and by cross-presenting viral antigens.36
They are also important in inducing regulatory T cells to
suppress allograft rejection in transplant models. Human DC
populations are not as well studied and therefore seem less
complex. Blood DCs are comprised of two major popula-
tions, the BDCA-1þ (CD1cþ ) myeloid DC, which is similar
to the mouse CD11bþ DC, and the BDCA-2þBDCA-4þ
PDC, which exhibits the properties of both mouse PDC and
CD8þ conventional DCs. In the kidney, activation of CD8þ
T cells in GN would be expected to require PDCs in humans
and PDC, CD8þ DC, or CD103þ DC in mouse for cross-
presentation (Figure 2).
Regarding DC subset functions, important gaps remain in
the understanding of CD8þ and CD4þ T-cell activation in
the kidney. Despite the overarching conclusion that CD8þ
T cells have significant roles in GN,26 further detailed,
mechanistic studies are needed. The first concerns the DC
type capable of mediating this cross-presentation. Kidney DC
has been reviewed recently.37 The kidney contains a large
population of CX3CR1þF4/80þ DCs, which lines the outer
medullary tubules and is prevalent elsewhere. These DCs are
CD8 and seem to correspond to the CD11bþ splenic DCs.
In gut and lungs CX3CR1þ DCs are CD11bþ , whereas
CD8þ and CD103þ DCs are CX3CR1. Thus, it is likely that
the CX3CR1þ DCs lining the kidney tubules are responsible
only for CD4þ T-cell activation, whereas CD8þ or CD103þ
DC populations that are likely to cross-present to CD8þ
T cells have not been studied. CD103þ DCs have been
identified in the kidney as a significant DC population (Sung
SJ, unpublished). It is reasonable to speculate that CD103þ
DCs along with PDCs and CD8þ DCs are the principal
CD8þ T-cell-stimulating DC populations and this hypoth-
esis needs to be examined. CD103þ DCs have the additional
advantage of being able to traverse the epithelial tight
junctions as in lungs31,32 and directly capture tubular
proteins for CD8þ T-cell cross-presentation (Figure 2). This
direct access of DC to the tubular lumen raises the second
question of the relative roles TECs and DCs have in accessing
antigens in the tubular space. DC types other than CD103þ
DCs may also be able to upregulate tight junction proteins
upon activation to access the tubular lumen directly. The
third question on the pathway of MHC-I loading by peptides
to form exogenous proteins has been addressed in human
PDCs and mouse bone-marrow-derived DCs.38,39 In these
DCs, exogenous proteins are processed and loaded onto
MHC-I molecules directly in the endosomes without
transversing the cytosol and without the involvement of
cytosolic proteosomes. For particulate antigens such as
apoptotic cells and large debris, phagosomes have also been
shown to be an important site for MHC-I loading of peptides
from ingested particles.27 Thus, proteosomes may have some
role in albumin presentation to CD8þ T cells, as suggested
by Macconi.27 However, it should not be surprising that
direct endosome loading of MHC-I by tubular proteins is
found to be the predominant mechanism. Receptor traffick-
ing may also contribute to cross-presentation. Antigens taken
up by DEC205 and mannose receptors induce robust cross-
presentation,28,40 which may be a result of the receptors
targeting antigens either to the correct cross-presenting DC
type or to a MHC-I processing and targeting compartment.
The existence of an intracellular receptor targeting pathway
for cross-presentation, if proven, can explain the functional
specificities of DC subsets in cross-presentation by their
preferential expression of MHC-I pathway targeting receptors
such as DEC205. Regarding the last question on the role of
CD4þ T cells in CD8þ transgenic OT-I T-cell activation, it
has been shown that CD4þ T-cell help is needed for
secondary CD8þ T-cell responses.41 This explains the
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Figure 2 |Processing of tubular proteins by renal dendritic
cells. Uptake and presentation of tubular proteins by renal DCs.
The figure shows the potential pathways by which tubular
antigens are internalized, processed, and presented to CD8þ and
CD4þ T-cells in the kidney draining lymph nodes. DC subsets in
the interstitium internalize antigens in the tubular lumen either
directly by inserting pseudopods into the lumen (CD103þ DCs) or
indirectly by internalizing antigen transported and/or processed
by transcellular antigen transport through tubular epithelial cells
(TECs). The presence of all DC types shown has been published,
except for CD103þ DCs, which have been identified in
preliminary studies (Sung SJ). For cross-presentation, antigens can
be directly processed in the endosomes and the MHC-I molecules
are loaded by the released peptides and presented to CD8þ
T cells. Other possible pathways of exogenous antigen loading—
by transit through the cytosol with processing by proteosomes
and MHC-I loading in the endoplasmic reticulum, and processing
and MHC-I loading in the phagosomes—are not shown. In cross-
presentation in the KDLNs, CD4þ T-cell help is shown. Cross-
presentation by CD11bþ DCs has been shown to be much
inferior to other DC types and is not shown. The main functions of
CD8þ T cells and CD4þ helper cells, but not those of Treg cells,
are shown.
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requirement for activated OT-II cells in GN induction in the
model of Heymann et al.26 What is not addressed is the
mechanism by which antigenic tolerance in the kidney is
broken by the transgenic T-cell transfers. Recent data indicate
that T-cell-mediated tolerance in peripheral organs is mostly
regulated by either IL-10-producing Tr1 or Foxp3þCD4þ
regulatory T cells.42,43 In the study of Heymann et al., the
balance between conventional T cells and regulatory T-cell
function is upset by the repeated injection of activated OT-II
cells, resulting in a more favorable T helper cell effect. In GN,
the imbalance of T helper versus regulatory T-cell function in
the diseased state may be small. Thus, manipulating
regulatory T-cell numbers in the kidney may constitute a
significant strategy for disease intervention.
THE GLOMERULOTUBULAR FEEDBACK LOOP
The studies from Macconi and Heymann provide significant
insight into the relationship between glomerular injury, TIN,
and damage (Figure 3). A common link in both the RMR and
transgenic podocyte models is the presence of protein in the
ultrafiltrate, which can be degraded by TECs and possibly
directly processed by DCs, and presented to T cells. These
proteins consist of multiple self-antigens (albumin) and
innumerable other proteins and peptides (i.e., fragments of
GBM and other cryptic glomerular antigens).44 These
peptides are likely involved in a continuing state of tolerance
maintenance, or, under certain circumstances, can initiate an
autoimmune state. A vicious cycle would be perpetuated with
a continuing supply of antigen to the immune system and the
interstitium with a de facto delayed hypersensitivity reaction
in the interstitium. However, as clinicians, we have seen many
patients with minimal change disease, membranous nephro-
pathy, and other proteinuric states with no interstitial disease.
A clue to this conundrum may lie in the fact that in the
normal state, DC uptake of antigen and cross-presentation
results in apoptosis of CD8þ cells without production of
inflammatory cytokines, with induction of tolerance.45 On
the other hand, in the presence of injured cells, the process of
cross-presentation to CD8þ cells results in active immunity
as postulated by Matzinger, secondary to so-called danger
signals or damage-associated molecular patterns (DAMPs).46
In this latter scenario, the presence of DAMPs results in
CD4þ help and CD8þ CTL activation and initiation of
tissue injury and autoimmunity. Emerging evidence has
shown that endogenous cytoplasmic and nuclear constitu-
ents, likely released from necrotic rather than apoptotic cell
death, have the potential to engage toll-like receptors and
augment inflammatory damage.47–49 These various danger
signals thus amplify the original immunological or non-
immunological damage and drive progression of injury-
induced organ damage. Other questions remain from both
the Macconi and Heymann studies. In the Heymann study,
what happened to the animals after the injection of OT-I and
OT-II cells stopped? Did suppressor mechanisms restore
normalcy to the animals or was a chronic process initiated?
How did ovalbumin become expressed in parietal epithelial cells?
How did ovalbumin-specific T cells congregate outside of
Bowman’s capsule and elicit glomerular damage as opposed to
being inside Bowman’s capsule as described by Wu et al.16 for
GBM antigen-specific T cells? How does proteinuria result in or
contribute to TIN in some situations but not others? If it is
DAMPs, how is that involved and what are the specifics? Why is
chronic TIN not associated with significant glomerular damage?
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Figure 3 |The glomerulotubular feedback loop. The figure
depicts the glomerulotubular feedback loop involving new
paradigms as described by Macconi and Heymann. Under normal
circumstances the glomerular filtrate contains many peptides,
proteins, and other substances that are filtered or shed into the
urinary space. These are taken up by dendritic cells directly from
the tubular lumen or after processing by tubular epithelial cells
(TECs). Normally, cell death is affected by apoptosis with the
presentation of these antigens to T cells without inflammatory
cytokines, resulting in tolerance and suppression. Even proteinuria
in this circumstance, consisting of a large amount of self-antigens,
is not associated with damage sans an inflammatory process. On
the other hand, damaged kidney, whether by reduced mass or by
autoimmune injury, induces cell necrosis rather than apoptosis,
with the release of damage-associated molecular patterns
(DAMPs), recruitment of exogenous cells, and stimulation of
endogenous cells to proliferate and elaborate the matrix and
inflammatory cytokines. The ultrafiltrate contains normal
constituents, but also now contains constituents released by renal
injury. This inductive phase may progress, depending on
regulatory feedback. However, when DCs process and present
antigen to T cells in this inflammatory milieu, the result is
tubulointerstitial nephritis (TIN) and feedback to the glomerulus,
either directly or through a periglomerular infiltrate, which
somehow communicates with the glomerulus across Bowman’s
capsule. Thus, a glomerulotubular feedback loop is established in
the setting of inflammation. This leads to further glomerular
damage with CD8þ CTL cross-presentation of previously
irrelevant or self-antigens and progression of TIN and
glomerulosclerosis.
Kidney International (2010) 77, 393–399 397
S-S Sung and WK Bolton: T cells and dendritic cells in glomerular disease m in i rev iew
and instead circulating DCs are recruited in the model described
by Heymann et al.?
In conclusion, the pivotal studies in the Macconi and
Heymann papers show a link between the glomerulus and the
tubulointerstitium in the development and progression of
chronic kidney disease. They provide a mechanism whereby
glomerular damage, whether by GN, RMR, or other
glomerular injury, can initiate a glomerulotubular feedback
loop resulting in amplified acute disease and progression of
chronic kidney disease. It seems likely that even though the
initial GN comes under control, the ‘second wave’ will
continue to increase interstitial and glomerular damage.
Many steps need to be elaborated to better understand the
pathogenesis and the interrelationship between these com-
partments and how intervention can have an impact on the
clinical course of these diseases in humans. A better
understanding of these issues provides the opportunity for
exciting, novel therapeutic interventions, which may be
broadly applicable to many different glomerular processes,
and even to the enormous problem of chronic kidney disease.
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